Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Entera Bio Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units. PALENIK, JEFFREY T is the busiest examiner, with 1 pending matter.
The pending work is distributed across two examination channels. That arrangement may produce different approaches to biological, formulation, or therapeutic claim language, so each action should be reviewed on its own record while maintaining consistent definitions for shared technical concepts.
The busiest-examiner field identifies only 1 pending matter for that examiner, which indicates no concentration in the available assignment data. A coordinated response strategy can still help align amendments and evidence without assuming that arguments developed for one application will resolve the other.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALENIK, JEFFREY T | 1 | 53.5% | +27.0% |
| REYNOLDS, FRED H | 1 | 32.9% | +39.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18798864 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | PALENIK, JEFFREY T | — |
| 15549394 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE | REYNOLDS, FRED H | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1658 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18798864 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | PALENIK, JEFFREY T | 1615 | §103 | Final Rejection | — | Pending | Aug 09, 2024 |
| 15549394 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS WITH CONTROLLED ABSORPTION PROFILE | REYNOLDS, FRED H | 1658 | §103Other | Final Rejection | — | Pending | Aug 08, 2017 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEntera Bio Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jeffrey T Palenik has the most, with 1 of Entera Bio Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
